Taiho Pharmaceutical unveils data on 8 novel anticancer compounds

Data will showcase potentially first- or best-in-class compounds

2012-11-06

(Press-News.org) DUBLIN, November 6, 2012 – Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies. The data being presented during the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from November 6 – 9, 2012 in Dublin, Ireland underscore Taiho's steadfast commitment to improving cornerstone anti-metabolic cancer agents and developing novel molecular targeted therapies that can be used alone or in combination worldwide.

"The data being presented demonstrate Taiho's ability to develop novel molecular targeted agents as well as next generation cytotoxic therapies, and underscore our continued commitment to developing investigational anticancer drugs that have the potential to improve treatment options available to cancer patients," said Masayuki Kobayashi, Taiho Pharmaceutical's president. "Our strategy surrounding innovative research and clinical development reinforces Taiho's pursuit of becoming a top-ten oncology company in the next decade."

Rapid Advancement Taiho established a foundation of innovative product development 50 years ago, and the Company is committed to achieving efficiencies to effectively yield rapid results. This commitment is best demonstrated by the recent movement of the TAS-102 antitumor agent through preclinical and clinical development. Preclinical results being presented at the EORTC-NCI-AACR Symposium show that TAS-102 exhibited marked tumor growth delay after drug treatment due to FTD incorporation into DNA when evaluated using a well-recognized animal model for breast cancer, and a survival benefit in a colon cancer model.

A Phase II study of TAS-102, conducted in Japan, demonstrated an improvement in overall survival of patients with metastatic colorectal cancer. Taiho took the encouraging results from this Phase II study and completed the required western Phase I studies to initiate a global Phase III program within a 15 month period.

Exploring New Treatment Options – Alone and in Combination Taiho has established a seamlessly connected research network, consisting of Tsukuba Research Center, Tokushima Research Center, the Taiho Clinical Development Center, and Taiho Pharma USA. The integrated network supports the discovery and development of numerous treatments. The Company's research achieves the highest standards of drug discovery by letting science guide its development path, and then applying modern technology and innovation to achieve that end. Investigational drugs stemming from this research are being examined as potential stand-alone products, or ones that can be used in combination with existing therapies to potentially enhance the safety and efficacy profile of current cancer options.

Highlights of the preclinical results of Taiho's investigational drugs being presented at the EORTC-NCI-AACR Symposium include: TAS-114, a first-in-class dUTPase (deoxyuridine 5'-triphosphate nucleotidehydrolase) and DPD (dihydropyrimidine dehydrogenase) dual inhibitor, was evaluated in three preclinical data sets in combination with a capecitabine-based chemotherapy as well as with S-1, and showed an impact on key pathway regulation and improvements in cytotoxicity of FU in vitro. Phase I studies are underway to explore the use of TAS-114 in combination with capecitabine, and separate studies examining the compound in combination with S-1. TAS-114 is being developed for potential use in treating solid tumors. TAS-115, a dual inhibitor of hepatocyte and vascular endothelial growth factor receptors, suppressed prostate cancer cell proliferation and osteoclast differentiation following bone resportion. Additionally, the combination of hepatocyte growth factor receptor gene expression signature and hepatocyte growth factor may represent a promising therapeutic biomarker for TAS-115. Taiho is developing TAS-115 as a potential treatment for solid tumors, and a Phase I study is underway. TAS-116, a HSP90 inhibitor, showed a high tumor/retina concentration ratio that may be important in minimizing ocular toxicity, which is a known class effect of this class of agents. TAS-117, an AKT inhibitor, in combination with taxanes, enhanced apoptosis induction and exhibited synergistic antitumor activity in in vitro and in vivo models. TAS-2104, a highly selective Aurora A inhibitor, was found to enhance anti-proliferation activity by taxanes, suggesting that the compound is suitable to test clinically in combination with taxanes. TAS-2913, a mutant-selective epidermal growth factor receptor inhibitor, was studied in vitro and findings suggest it may represent a new therapeutic option in the treatment of non-small cell lung cancer that is resistant to epidermal growth factor receptors and tyrosine kinase inhibitors. TAS-2985, a small molecule inhibitor of fibroblast growth factor receptors (FGFRs), demonstrated strong tumor growth inhibition in animal xenograft models, and a pharmacodynamic assay suggested the compound inhibits FGFR activity selectively in a human tumor xenograft model. Additionally, in vitro, the molecule selectively inhibited growth of human cancer cell lines in a FGFR-dependent manner.

### About Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to a society enriched by smiles." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit http://www.taiho.co.jp/english/

About Otsuka Holdings Co., Ltd. The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy "Otsuka-people creating new products for better health worldwide." The Otsuka Group has business operations in 24 countries and regions around the world. For more information, please visit the company's website at www.otsuka.com/en/.

ELSE PRESS RELEASES FROM THIS DATE:

Rebuilding a whole heart for children born with only half of 1

2012-11-06

Boston, Mass.—Using a combination of surgical procedures developed over the last 11 years, surgeons at Boston Children's Hospital have established a new approach for rebuilding the heart in children born with a severe heart defect called hypoplastic left heart syndrome (HLHS). This "staged left ventricle recruitment" (SLVR) strategy uses the existing standard single-ventricle treatment for HLHS and additional procedures to spur the body's capacity for healing and growth and encourage the small left ventricle in these children to grow and function. Members of Boston Children's ...

How bacteria talk to each other and our cells

2012-11-06

Bacteria can talk to each other via molecules they themselves produce. The phenomenon is called quorum sensing, and is important when an infection propagates. Now, researchers at Linköping University in Sweden are showing how bacteria control processes in human cells the same way. The results are being published in the journal PLOS Pathogens with Elena Vikström, researcher in Medical Microbiology, as the main author. When an infection is signaled, more and more bacteria gather at the site of the attack – a wound, for example. When there are enough of them, they start ...

Combating a crisis: Global burden of preterm birth can be reduced if critical actions are taken

2012-11-06

New surveys of researchers and funders reveal a lack of consensus regarding researching and developing interventions to prevent prematurity and stillbirth, according to an article published in the American Journal of Obstetrics and Gynecology ahead of World Prematurity Day on November 17. Authored by Michael G. Gravett, MD, scientific director of the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's, and Craig E. Rubens, MD, PhD, executive director of GAPPS, the article outlines significant opportunities to enhance research ...

New bacteria to fight against intestinal inflammation

2012-11-06

This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis. The results of this research were published in the Science Translational Medicine review on 31 October 2012. In France, nearly 200,000 individuals suffer from chronic inflammatory bowel disease, known as IBD, (specifically Crohn's disease and ulcerative colitis). ...

Supercomputing for a superproblem: A computational journey into pure mathematics

2012-11-06

A world-famous mathematician responsible for solving one of the subject's most challenging problems has published his latest work as a University of Leicester research report. This follows the visit that famed mathematician Yuri Matiyasevich made to the Department of Mathematics where he talked about his pioneering work. He visited UK by invitation of the Isaac Newton Institute for Mathematical Sciences. In 1900, twenty-three unsolved mathematical problems, known as Hilbert's Problems, were compiled as a definitive list by mathematician David Hilbert. A century later, ...

New strategy for fingerprint visualization developed at Hebrew University

2012-11-06

Jerusalem, Nov. 6, 2012 -- Identifying fingerprints on paper is a commonly used method in police forensic work, but unfortunately it is not easy to make those fingerprints visible. Now, scientists at the Hebrew University of Jerusalem have developed a new approach for making such fingerprints more readily readable. The new method, created by a team headed by Prof. Yossi Almog and Prof. Daniel Mandler of the Institute of Chemistry at the Hebrew University, uses an innovative chemical process to produce a negative of the fingerprint image rather than the positive image ...

Strange diet for methane consuming microorganisms

2012-11-06

This press release is available in German. Methane is formed under the absence of oxygen by natural biological and physical processes, e.g. in the sea floor. It is a much more powerful greenhouse gas than carbon dioxide. Thanks to the activity of microorganisms this gas is inactivated before it reaches the atmosphere and unfolds its harmful effects on Earth's climate. Researchers from Bremen have now proven that these microorganisms are quite picky about their diet. All life on Earth is based on carbon and its compounds. Cell components of all creatures contain carbon. ...

Early treatment sparks striking brain changes in autism

2012-11-06

When given early treatment, children with autism spectrum disorders (ASD) made significant improvements in behavior, communication, and most strikingly, brain function, Yale School of Medicine researchers report in a new study. The study was published in the current issue of the Journal of Autism and Developmental Disorders by Yale Child Study Center researchers Fred Volkmar, M.D., Kevin A. Pelphrey, and their colleagues. The results suggest that brain systems supporting social perception respond well to an early intervention behavioral program called pivotal response ...

HF patients treated by a cardiologist, rather than hospitalist, have fewer readmissions

2012-11-06

MINNEAPOLIS, MN – November 6, 2012 – When a cardiologist attends to heart failure patients, even when the severity of illness is higher, patients have reduced rates of hospital readmissions, compared with those patients who are treated by a hospitalist, according to a trial being presented today at the American Heart Association's scientific sessions in Los Angeles. Congestive heart failure (CHF) is the most common cause for hospital readmission in patients over the age of 65 years. Whereas efforts to reduce readmission rates have focused on transitions of care and short-term ...

Living abroad can bring success -- If you do it right

2012-11-06

"Travel broadens the mind" goes the old adage, and potential employers often agree, valuing the open-mindedness and creativity fostered by such worldliness. But according to new Tel Aviv University research, not all international experiences are created equal. "Although living abroad does help to hone creative abilities, not all individuals who have lived abroad derive an equal benefit from such experiences," explains Dr. Carmit Tadmor of TAU's Recanati School of Business, who conducted the study with Dr. Adam Galinsky of the Kellogg School of Management at Northwestern ...

Taiho Pharmaceutical unveils data on 8 novel anticancer compounds

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: